Catalyst Pharmaceuticals Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer
16 Agosto 2023 - 11:56AM
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a
commercial-stage, patient-centric biopharmaceutical company focused
on in-licensing, developing, and commercializing novel high-quality
medicines for patients living with rare diseases, today announced
that an abstract assessing the prevalence of Lambert-Eaton
myasthenic syndrome (“LEMS”) among patients with small cell lung
cancer (“SCLC”) in the United States, was accepted and will be
presented at the IASLC 2023 World Conference of Lung Cancer
(#WCLC23) hosted by the International Association for the Study of
Lung Cancer, happening September 9-12, 2023 in Singapore.
The abstract details the results from a study
analyzing real-world data to determine the prevalence of LEMS
diagnoses among patients with SCLC in the United States. While
published data estimate that 3% of patients with SCLC have a
concurrent LEMS diagnosis, this analysis of oncology healthcare
claims between 2017-2022 found that 0.16 – 0.24% of patients with
SCLC had LEMS claims, indicating a 10-fold underdiagnosis of LEMS
in patients with SCLC. The authors hypothesize non-specific LEMS
symptoms, such as fatigue and weakness, may have been attributed to
SCLC, leading to underdiagnosis. These data imply that the overall
population of LEMS is significantly larger than previous
estimates.
Presentation
Details:Poster Session: P2.31 - Global
Health, Health Services, and Health Economics – Real World
DataTitle: Lambert-Eaton Myasthenic Syndrome is
Underrecognized in Small Cell Lung Cancer: An Analysis of
Real-World DataDate Monday, September 11,
2023Time: 6:00 PM -7:30 PM Singapore Time (SST) /
6:00 AM – 7:30 AM U.S. Eastern Time (ET)Presenter:
David Morrell, MBA, SVP Marketing at Catalyst Pharmaceuticals
“The results from the study have brought to
light significant insights into the relationship between small-cell
lung cancer and Lambert Eaton myasthenic syndrome, or LEMS. This
research adds to the growing body of evidence illustrating that the
prevalence of LEMS, including individuals with small cell lung
cancer, is now estimated to be about 3,600 to 5,400 people (1-6) in
the United States, of which a substantial number currently remain
undiagnosed and untreated,” stated Patrick J. McEnany, Chairman and
CEO of Catalyst. “Our hope is that this study will contribute to
heightened awareness, leading to early diagnoses and ultimately
improving the quality of life for those affected by LEMS and small
cell lung cancer.”
Learn more about #WCLC23 here:
https://wclc2023.iaslc.org/
About Catalyst Pharmaceuticals
With exceptional patient focus, Catalyst is
committed to developing and commercializing innovative
first-in-class medicines that address rare neurological and
epileptic diseases. Catalyst’s flagship U.S. commercial
product is FIRDAPSE® (amifampridine) Tablets 10 mg, approved
for the treatment of Lambert-Eaton myasthenic syndrome ("LEMS") for
adults and for children ages six to seventeen. In January
2023, Catalyst acquired the U.S. commercial rights to
FYCOMPA® (perampanel) CIII, a prescription medicine approved
in people with epilepsy aged four and older alone or with other
medicines to treat partial-onset seizures with or without
secondarily generalized seizures and with other medicines to treat
primary generalized tonic-clonic seizures for people with epilepsy
aged 12 and older. Further, Canada’s national healthcare
regulatory agency, Health Canada, has approved the use of
FIRDAPSE for the treatment of adult patients
in Canada with LEMS. Further, on July 18, 2023,
Catalyst acquired an exclusive license for North
America for vamorolone, a promising best-in-class dissociative
anti-inflammatory steroid treatment for Duchenne Muscular
Dystrophy. Vamorolone has received FDA Orphan Drug and Fast
Track designations and has been granted a PDUFA action date
of October 26, 2023.
For more information about Catalyst
Pharmaceuticals, Inc., visit the Company’s website
at: www.catalystpharma.com. For the Full Prescribing and
Safety Information for FIRDAPSE®, please
visit www.firdapse.com. For the Full Prescribing Information
for FYCOMPA®, please visit www.fycompa.com.
References:
- American Cancer Society. Key Statistics for Lung Cancer. 2023.
https://www.cancer.org/cancer/types/lung-cancer/about/key-statistics.html
- Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Nat Rev Dis
Primers 2021; 7(1):
- Titulaer MJ, Maddison P, Sont JK, et al. J Clin Oncol 2011; 29:
902–08.
- Wirtz PW, Lang B, Graus F, et al. J Neuroimmunol 2005;
164(1-2): 161-5.
- Gozzard P, Woodhall M, Chapman C, et al. Neurology 2015; 85(3):
235-9.
- Payne M, Bradbury P, Lang B, et al. J Thorac Oncol 2010; 5(1):
34-8.
Forward-Looking Statements
This press release contains forward-looking
statements. Forward-looking statements involve known and unknown
risks and uncertainties, which may cause Catalyst's actual results
in future periods to differ materially from forecasted results. A
number of factors, including those factors described in Catalyst's
Annual Report on Form 10-K for the fiscal year 2022 and its other
filings with the U.S. Securities and Exchange
Commission (“SEC”), could adversely affect Catalyst. Copies of
Catalyst's filings with the SEC are available from
the SEC, may be found on Catalyst's website, or may be
obtained upon request from Catalyst. Catalyst does not undertake
any obligation to update the information contained herein, which
speaks only as of this date.
Source: Catalyst Pharmaceuticals, Inc.
Investor Contact
Mary Coleman
Catalyst Pharmaceuticals, Inc.
(305) 420-3200
mcoleman@catalystpharma.com
Media Contact
David Schull
Russo Partners
(858) 717-2310
david.schull@russopartnersllc.com
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024